OncoMatch/Clinical Trials/NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Is NCT07318558 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Sacituzumab tirumotecan and Bevacizumab for ovarian neoplasms.
Treatment: Sacituzumab tirumotecan · Bevacizumab · Rescue Medications — Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO 2014 STAGE III, FIGO 2014 STAGE IV (other)
FIGO 2014 Stage III or Stage IV
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Cannot have received: systemic anticancer therapy
Exception: first-line platinum-based chemotherapy required by inclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mount Sinai Cancer Center ( Site 0029) · Miami Beach, Florida
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) · Orlando, Florida
- Winship Cancer Institute of Emory University ( Site 0037) · Atlanta, Georgia
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055) · Fort Wayne, Indiana
- Women's Cancer Care ( Site 0018) · Covington, Louisiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07318558 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage FIGO 2014 STAGE III or FIGO 2014 STAGE IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages